Document is current
Any future updates will be listed below
-
Authors
Slack, R. J.
Macdonald, S. J. F. https://orcid.org/0000-0002-4859-8246
Roper, J. A. https://orcid.org/0000-0002-8910-6033
Jenkins, R. G. https://orcid.org/0000-0002-7929-2119
Hatley, R. J. D. https://orcid.org/0000-0002-3172-2511
- License Information
-
More Information
Article History
Accepted: 26 July 2021
First Online: 17 September 2021
Competing interests
: R.J.D.H. and S.J.F.M. hold GSK shares and are applicants on GSK integrin patents. R.J.S. and J.A.R. hold GSK shares and are currently Galecto, Inc. employees and shareholders. R.G.J. reports grants from GlaxoSmithKline, grants and personal fees from Pliant Therapeutics, grants from Biogen, during the conduct of the study; personal fees from Galapagos, other from Galecto, personal fees and other from GlaxoSmithKline, personal fees and other from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Pliant, personal fees from Bristol-Myers Squibb, personal fees from Chiesi, personal fees from Roche/Promedior, personal fees and other from RedX, other from NuMedii, other from Nordic Biosciences, personal fees from Veracyte, personal fees from PatientMPower, personal fees from Resolution Therapeutics, personal fees from Vicore, outside the submitted work; he is supported by a National Institute of Health Research Professorship (NIHR ref: RP-2017-08-ST2-014). He is a trustee for Action for Pulmonary Fibrosis.
